- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2041–2064
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Parkinson Disease
- Interventions
- DaTscan
- Drug
- Lead sponsor
- Ken Marek, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
- Conditions
- Hepatitis B
- Interventions
- DxN HBV Assay
- Diagnostic Test
- Lead sponsor
- Beckman Coulter, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- La Jolla, California • Minneapolis, Minnesota • Jackson, Mississippi + 5 more
- Conditions
- Spine Fusion
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Seattle, Washington • Wenatchee, Washington
- Conditions
- End Stage Renal Disease
- Interventions
- Graft placement surgery plus Trinam therapy
- Procedure
- Lead sponsor
- Ark Therapeutics Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more
- Conditions
- Human Papillomavirus-Related Carcinoma
- Interventions
- Best Practice, Educational Intervention, Interview, Questionnaire Administration, Training and Education, Vaccination
- Other · Behavioral · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- University Park, Pennsylvania • Seattle, Washington
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
- Interventions
- TH-4000 (Tarloxotinib)
- Drug
- Lead sponsor
- Rain Oncology Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Interventions
- Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 121
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Autism
- Interventions
- secretin, synthetic porcine, secretin, biologically derived porcine
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
- Interventions
- Ziftomenib, Cytarabine, Fludarabine
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Interventions
- Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 75
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
- Conditions
- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 45 more
- Conditions
- Neoplasms, Hematologic
- Interventions
- 120 mg LY2784544
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 23
- States / cities
- Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- EDG-7500
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Patent Foramen Ovale
- Interventions
- Cardiox FDS
- Device
- Lead sponsor
- Cardiox Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 4 more
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- BL-M14D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Glendale, California • Long Beach, California + 19 more
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Cincinnati, Ohio • Portland, Oregon + 1 more
- Conditions
- Malignant Glioma
- Interventions
- Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
- Conditions
- Diagnostic Self Evaluation, Central Nervous System Diseases
- Interventions
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more